

Transasia launches India's first high sensitivity Hepatitis C testing kit

26 October 2021 | News

Reduces window period to less than 28 days, resulting in earlier diagnosis

Erba Lisa® HCV Gen4 Ag+Ab

India's 1st indigenously developed 4th Gen ELISA Kit



Transasia Bio-Medicals, based in Mumbai, has announced the launch of a high sensitivity testing kit for the hepatitis C virus. Based on the latest method, the ErbaLisa HCV Gen 4 Ag+Ab kit, is India's first and only indigenously developed 4th gen ELISA kit and has been evaluated by the National Institute of Biologicals (NIB).

ErbaLisa HCV Gen4 Ag+Ab kit is intended for the detection of HCV core antigen (viral protein) and anti-HCV antibodies, simultaneously, in human serum and plasma. It has a sensitivity of 100 per cent and a specificity of 99.67 per cent.

The simultaneous detection of antigen and antibodies with ErbaLisa HCV Gen4 Ag+Ab will greatly aid in screening HCV more accurately, as the window period for HCV detection will be reduced to less than 28 days.

The ErbaLisa HCV Gen4 Ag+Ab kit is fully adaptable to reputed automated ELISA processors. The assay can be run in 150 mins only and is pre-programmed on Transasia's Elan 30s, a fully automated ELISA system and Lisa XL, a fully automated, six plate microprocessor.